IOL Chemicals and Pharmaceuticals Limited (IOLCP.NS)
INR 65.35
(-5.43%)
INR 65.35
(-5.43%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 22.44 Billion INR | 10.99% |
| 2022 | 20.22 Billion INR | 3.05% |
| 2021 | 19.62 Billion INR | 21.88% |
| 2020 | 16.1 Billion INR | 36.96% |
| 2019 | 11.75 Billion INR | 24.81% |
| 2018 | 9.41 Billion INR | 14.63% |
| 2017 | 8.21 Billion INR | 0.44% |
| 2016 | 8.18 Billion INR | 5.44% |
| 2015 | 7.75 Billion INR | 10.58% |
| 2014 | 7.01 Billion INR | -5.33% |
| 2013 | 7.41 Billion INR | 1.96% |
| 2012 | 7.26 Billion INR | 5.81% |
| 2011 | 6.86 Billion INR | 12.64% |
| 2010 | 6.09 Billion INR | 20.0% |
| 2009 | 5.08 Billion INR | 21.08% |
| 2008 | 4.19 Billion INR | 73.96% |
| 2007 | 2.41 Billion INR | 36.49% |
| 2006 | 1.76 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 22.44 Billion INR | 0.0% |
| 2023 FY | 22.44 Billion INR | 10.99% |
| 2023 Q2 | 20.81 Billion INR | 0.0% |
| 2023 Q3 | 22.44 Billion INR | 7.83% |
| 2022 FY | 20.22 Billion INR | 3.05% |
| 2022 Q4 | 20.22 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 20.11 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 19.62 Billion INR | 21.88% |
| 2021 Q4 | 19.62 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 17.64 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 16.1 Billion INR | 36.96% |
| 2020 Q4 | 16.1 Billion INR | 0.0% |
| 2020 Q2 | 14.53 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 11.75 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 10.26 Billion INR | 0.0% |
| 2019 FY | 11.75 Billion INR | 24.81% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 9.41 Billion INR | 0.0% |
| 2018 Q2 | 8.34 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 9.41 Billion INR | 14.63% |
| 2017 Q2 | 8.33 Billion INR | 0.0% |
| 2017 FY | 8.21 Billion INR | 0.44% |
| 2017 Q4 | 8.21 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 7.91 Billion INR | 0.0% |
| 2016 Q4 | 8.18 Billion INR | 0.0% |
| 2016 FY | 8.18 Billion INR | 5.44% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 7.75 Billion INR | 10.58% |
| 2015 Q2 | 7.67 Billion INR | 0.0% |
| 2015 Q4 | 7.75 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 7.45 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 7.01 Billion INR | 0.0% |
| 2014 FY | 7.01 Billion INR | -5.33% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 7.31 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 7.41 Billion INR | 0.0% |
| 2013 FY | 7.41 Billion INR | 1.96% |
| 2012 FY | 7.26 Billion INR | 5.81% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 14.28 Billion INR | 0.0% |
| 2012 Q4 | 7.26 Billion INR | 0.0% |
| 2011 FY | 6.86 Billion INR | 12.64% |
| 2010 FY | 6.09 Billion INR | 20.0% |
| 2009 FY | 5.08 Billion INR | 21.08% |
| 2008 FY | 4.19 Billion INR | 73.96% |
| 2007 FY | 2.41 Billion INR | 36.49% |
| 2006 FY | 1.76 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -635.888% |
| Aarti Drugs Limited | 24.32 Billion INR | 7.727% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 13.079% |
| Ajanta Pharma Limited | 46.38 Billion INR | 51.613% |
| Alembic Limited | 23.28 Billion INR | 3.623% |
| Alkem Laboratories Limited | 155.74 Billion INR | 85.59% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 65.179% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -108.195% |
| Bal Pharma Limited | 3.2 Billion INR | -600.523% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -4666.931% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -84.896% |
| Brooks Laboratories Limited | 904.45 Million INR | -2381.497% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -1419.756% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 16.793% |
| Divi's Laboratories Limited | 154.7 Billion INR | 85.492% |
| Eris Lifesciences Limited | 70.48 Billion INR | 68.159% |
| Granules India Limited | 55.2 Billion INR | 59.348% |
| Ind-Swift Limited | 6.54 Billion INR | -242.933% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -933.914% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 43.808% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 80.565% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -834.927% |
| Medicamen Biotech Limited | 2.94 Billion INR | -662.047% |
| Medico Remedies Limited | 961.95 Million INR | -2233.17% |
| Wockhardt Limited | 76.49 Billion INR | 70.658% |
| Orchid Pharma Limited | 15.53 Billion INR | -44.439% |
| RPG Life Sciences Limited | 5.12 Billion INR | -337.616% |
| Shilpa Medicare Limited | 30.93 Billion INR | 27.441% |
| Sigachi Industries Limited | 6.94 Billion INR | -223.328% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 4.355% |
| Unichem Laboratories Limited | 31.69 Billion INR | 29.184% |
| Vaishali Pharma Limited | 799.55 Million INR | -2707.054% |
| Wanbury Limited | 3.43 Billion INR | -553.405% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 92.335% |
| FDC Limited | 24.68 Billion INR | 9.063% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -511.769% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -193.337% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 94.208% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 21.261% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -92.635% |
| Laurus Labs Limited | 83.87 Billion INR | 73.24% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -573.137% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -2.435% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -2108.814% |
| Hester Biosciences Limited | 6.62 Billion INR | -238.856% |
| Ipca Laboratories Limited | 111.01 Billion INR | 79.783% |
| Venus Remedies Limited | 6.26 Billion INR | -258.056% |
| ZIM Laboratories Limited | 4.46 Billion INR | -402.303% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 95.02% |
| Morepen Laboratories Limited | 12.93 Billion INR | -73.553% |
| Neuland Laboratories Limited | 18.32 Billion INR | -22.473% |
| Sequent Scientific Limited | 15.4 Billion INR | -45.704% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 0.43% |
| Valiant Laboratories Limited | 3.42 Billion INR | -554.941% |
| Windlas Biotech Limited | 6.26 Billion INR | -258.412% |
| Hikal Limited | 24.87 Billion INR | 9.76% |
| Innova Captab Limited | 13.2 Billion INR | -69.917% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -182.542% |
| Themis Medicare Limited | 5.66 Billion INR | -296.246% |
| Mankind Pharma Limited | 119.63 Billion INR | 81.239% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 84.369% |
| Sakar Healthcare Limited | 3.88 Billion INR | -477.473% |
| Albert David Limited | 4.97 Billion INR | -350.69% |
| Lupin Limited | 239.97 Billion INR | 90.647% |
| Gufic Biosciences Limited | 10.92 Billion INR | -105.429% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 97.374% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -220.496% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -454.633% |
| Piramal Enterprises Limited | 826.05 Billion INR | 97.283% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 85.098% |
| NATCO Pharma Limited | 69.06 Billion INR | 67.502% |
| Suven Life Sciences Limited | 2.84 Billion INR | -687.778% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -1159.663% |
| Strides Pharma Science Limited | 58.39 Billion INR | 61.567% |
| Indoco Remedies Limited | 21.44 Billion INR | -4.647% |
| Alpa Laboratories Limited | 1.82 Billion INR | -1128.989% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -1387.651% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -335.772% |